RT Journal Article
SR Electronic
T1 Evolution of COVID-19 pandemic: Power law growth and saturation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.05.20091389
DO 10.1101/2020.05.05.20091389
A1 Soumyadeep Chatterjee
A1 B. Shayak
A1 Ali Asad
A1 Shashwat Bhattacharya
A1 Shadab Alam
A1 Mahendra K. Verma
YR 2020
UL http://medrxiv.org/content/early/2020/05/08/2020.05.05.20091389.abstract
AB In this paper, we analyze the real-time infection data of COVID-19 epidemic for 21 nations up to April 20, 2020. We observe that China, South Korea, Australia, Hong Kong, and Switzerland have flattened their infection curves. For these nations, the total number of infected individuals (I(t)) exhibits a succession of exponential growth and power-law growth (t2, t, in sequence) before flattening of the curve. USA, Italy, UK, France, Spain, Germany, Belgium, Israel, Netherlands, India, and Sri Lanka have reached up to the linear growth (I(t) ~ t), but they are yet to flatten their curves. Russia and Singapore are still in the exponential growth regime. Such features of I(t) curves could be used for understanding and forecast of the epidemic evolution. Besides these detailed analysis, we compare the predictions of an extended SEIR model and a delay differential equation-based model with the reported infection data, and observed a general agreement between them.Competing Interest StatementThe authors have declared no competing interest.Funding StatementIndo-French (CEFIPRA) project 6104-1; INSPIRE fellowship (IF180094) of Department of Science & TechnologyAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe used the publicly available data from the website worldOmeter.info